Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Gina Gheorghe
 -- 2049 2023-01-11 09:11:53 |
2 update references and layout
Amina Yu
 + 9 word(s) 2058 2023-01-12 01:58:35 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ionescu, V.A.;  Gheorghe, G.;  Varlas, V.N.;  Stanescu, A.M.A.;  Diaconu, C.C. Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases. Encyclopedia. Available online: https://encyclopedia.pub/entry/40010 (accessed on 17 November 2024).
Ionescu VA,  Gheorghe G,  Varlas VN,  Stanescu AMA,  Diaconu CC. Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases. Encyclopedia. Available at: https://encyclopedia.pub/entry/40010. Accessed November 17, 2024.
Ionescu, Vlad Alexandru, Gina Gheorghe, Valentin Nicolae Varlas, Ana Maria Alexandra Stanescu, Camelia Cristina Diaconu. "Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases" Encyclopedia, https://encyclopedia.pub/entry/40010 (accessed November 17, 2024).
Ionescu, V.A.,  Gheorghe, G.,  Varlas, V.N.,  Stanescu, A.M.A., & Diaconu, C.C. (2023, January 11). Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases. In Encyclopedia. https://encyclopedia.pub/entry/40010
Ionescu, Vlad Alexandru, et al. "Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases." Encyclopedia. Web. 11 January, 2023.
Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases
Edit
This entry is adapted from the peer-reviewed paper 10.3390/gastroent14010002

Inflammatory bowel disease (IBD) refers to chronic conditions with a low mortality but high disability. The multisystemic nature of these diseases can explain the appearance of some extraintestinal manifestations, including liver damage. Abnormal liver biochemical tests can be identified in approximately one third of patients with IBD and chronic liver disease in 5% of them. Among the liver diseases associated with IBD are primary sclerosing cholangitis, cholelithiasis, fatty liver disease, hepatic amyloidosis, granulomatous hepatitis, drug-induced liver injury, venous thromboembolism, primary biliary cholangitis, IgG4-related cholangiopathy, autoimmune hepatitis, liver abscesses or the reactivation of viral hepatitis. The most common disease is primary sclerosing cholangitis, a condition diagnosed especially in patients with ulcerative colitis.

hepatobiliary impairments inflammatory bowel diseases disability treatment prognosis

1. Cholelithiasis

The prevalence of cholelithiasis in the general population ranges from 5.5% to 15% [1]. In Crohn’s disease (CD), the risk of developing gallstones is double (prevalence rate 11–34%), while in UC, no differences in the prevalence of gallstones compared to the general population were identified [1][2]. The risk factors for cholelithiasis in CD patients are age at CD diagnosis, disease duration (>15 years), ileo-colonic localization of the lesions, length of ileal resection (>30 cm), frequency of clinical recurrences (>3), long hospital stay, number of hospitalizations (>3) and total parenteral nutrition [3]. Among the pathophysiological mechanisms underlying cholelithiasis in CD are the following: bile acid malabsorption; solubilization of bilirubin by unabsorbed bile acids in the colon; dysbiosis with bile acid dysmetabolism; reduced gallbladder motility; activation of Th1-mediated immune response; primary sclerosing cholangitis (PSC) associated with inflammatory bowel disease (IBD); and hemolysis induced by drugs [4][5][6][7]. The only indication for cholecystectomy remains complicated cholelithiasis [8]. Even in patients with CD who require ileocolonic resection, prophylactic cholecystectomy is not recommended [9]. Navaneethan et al. demonstrated an increased risk of postoperative complications in IBD patients [10].

2. Non-Alcoholic Fatty Liver Disease (NAFLD)

The prevalence of NAFLD among patients with IBD varies between 33–55% [11][12][13][14]. A study that followed 384 patients with IBD, with no significant alcohol intake, reported the presence of NAFLD in 32.8% of them and the presence of significant liver fibrosis in 12.2% [12]. The independent predictors for NAFLD were higher body mass index (BMI), older age and higher triglycerides [12]. For liver fibrosis, the independent predictors were older age and higher body mass index (BMI) [12]. Extrahepatic diseases, such as chronic kidney disease and cardiovascular disease, proved to be more frequently diagnosed among patients with IBD and NAFLD compared to those with IBD alone [12]. The pathophysiological mechanisms that can explain the increased risk of NAFLD among patients with IBD are chronic relapsing inflammation, an alteration in intestinal microbiota, parenteral nutrition, potentially hepatotoxic drugs and surgery [13][14][15]. Moreover, dysbiosis has been associated with both the severity of IBD and NAFLD, which suggests a pathogenic link between the two conditions [13][14]. Restellini et al. suggested the need to initiate noninvasive screening strategies (transient elastography) among patients with IBD and high-risk factors of NAFLD [12]. The objectives of these screening strategies are early diagnosis and the early initiation of therapeutic measures, such as weight loss or lipid-lowering medication [12]. On the other hand, biological treatments used for IBD, such as infliximab, have been shown to improve liver histological changes in patients with NAFLD [16]. Monitoring adherence to treatment is also necessary. The absence of NAFLD secondary symptoms, such as upper right abdominal pain or asthenia, among some patients with chronic digestive disorders may explain the lower adherence to the therapeutic measures that NAFLD requires [12]. The importance of adherence to treatment derives from the risk of the evolution of this condition toward irreversible liver fibrosis and even cirrhosis.

3. Granulomatous Hepatitis

Granulomatous hepatitis is a rare complication of CD [17]. However, this condition can be secondary to treatment with mesalamine or sulfasalazine, or it can have malignant or infectious etiologies [18][19][20]. From a clinical point of view, granulomas are usually asymptomatic [17]. In extensive disease, hepatomegaly or jaundice can be detected [17]. A diagnosis is usually suggested by imaging identification of a liver mass or an unexplained increase in cholestatic enzymes [21]. A positive diagnosis is established by a liver biopsy [17]. The first-line treatment for granulomatous hepatitis, after the exclusion of infectious etiology, consists of systemic corticosteroids [22]. In case of corticosteroid resistance, immunomodulatory drugs such as azathioprine or methotrexate and anti-TNF-α agents can be used [23]. Paradoxically, cases of granulomatous hepatitis and extrapulmonary sarcoidosis have also been reported in patients with CD who are on anti-TNF-α treatment [24]. Decock et al. identified 90 cases of sarcoidosis-like lesions associated with anti-TNF therapy in the literature [24]. In most cases, these were patients with rheumatic disease (rheumatoid arthritis, ankylosing spondylitis, psoriasiform arthritis) and the most prescribed drug among them was etanercept. Only six patients had IBD as the underlying disease [24]. In 71 of these patients, the partial remission of liver disease was obtained by withdrawing biological treatment, initiating treatment with corticosteroid or both therapeutic measures [24]. The reintroduction of treatment with anti-TNF agents led to the reactivation of liver disease in 7 out of 20 patients [24].

4. Hepatic Amyloidosis

Secondary amyloidosis can be a complication of chronic inflammatory diseases. This condition is rare among IBD patients, occurring in less than 1% of them [1]. If in CD the prevalence of hepatic amyloidosis varies between 0.9–3%, in UC it does not exceed 0.07% [1]. Hepatic amyloidosis is more common in men and the average age at diagnosis is approximately 40 years. Additionally, a more frequent association of this condition with the colonic localization of CD has been reported [1]. The patients are usually asymptomatic, and a diagnosis is suggested by the identification of hepatomegaly during imaging examination. The treatment consists of controlling the underlying CD and reducing the release of acute-phase reactant serum amyloid A [1][25]. Gottenberg et al. claimed that anti-TNFα agents can reduce the release of amyloid precursors and the formation of amyloid deposits, contributing to the clinical improvement of these patients [25]. Another drug with long-term benefits in patients with amyloidosis and CD has been shown to be colchicine [26]. Secondary systemic amyloidosis was associated with an increased risk of infections, sepsis and multi-organ system involvement, but without influencing in-hospital mortality in IBD patients [27].

5. Venous Thromboembolism (VTE)

VTE is a condition with significant morbidity and mortality. In the United States, more than 500,000 hospitalizations and 100,000 deaths attributed to VTE are registered annually [28]. Compared to the general population, patients with IBD have a two-to three-fold higher risk of developing VTE [29]. Bruining et al. reported an incidence rate for portal thrombosis of 1.7% among patients with CD [30]. In patients with IBD undergoing surgery, the incidence rate of superior mesenteric thrombosis can reach up to 4.8% [31]. The pathophysiological mechanisms of VTE in IBD are incompletely elucidated. Currently, the following several risk factors are incriminated: age; genetics factors; pregnancy; active and more extensive disease; hospitalization; surgery; and medications (corticosteroids or tofacitinib) [32]. IBD is characterized by a procoagulant status attributed to the upregulation of inflammatory and coagulation systems [33]. In these patients, during an IBD flare, the following were identified: increased levels of fibrinogen; products of fibrin; thrombin formation; von Willebrand factors; and coagulation factors V, VII, VIII, X, XI and XII [34][35]. During active disease periods, lower levels of antithrombin and protein S, thrombocytosis and increased platelet activity were also highlighted [36][37]. The increased risk of thrombotic events seems to be particular to IBD, not occurring in other chronic inflammatory diseases, such as celiac disease or rheumatoid arthritis [30][38]. Compared to age, there was a significantly higher risk of VTE in young people, but also in elderly patients [39]. Nylund et al. reported an increased risk of VTE among hospitalized IBD adolescents compared to non-IBD hospitalized adolescents [40]. Another study that followed 872,122 patients with IBD reported an increase in the risk of VTE with advancing age [41]. If in the age group 31–40 years, the risk of VTE was 2.1; in the age group 41–50 years, the risk was 2.08; in the age group 51–65 years, the risk was 3.74; in the age group 66–80 years, the risk was 4.04; and in the age group > 80 years, the risk reached 3.06 [42].
The first-line paraclinical investigation that can identify portal vein thrombosis is abdominal ultrasonography, but the gold standard remains the CT scan. The therapeutic management of patients with IBD and portal thrombosis includes the following: cessation of smoking and consumption of oral contraceptives; anticoagulant treatment with low-molecular-weight heparin (LMWH) or warfarin; and, in severe cases, thrombolysis; surgical interventions; or intravascular thrombectomy devices [43].
Currently, there are no clear recommendations regarding VTE prophylaxis among IBD patients. However, all guidelines recommend VTE prophylaxis in hospitalized patients, with no hemodynamically significant bleeding, during an IBD flare [39]. The extent of post-discharge VTE prophylaxis in patients with high thrombotic risk remains unclear [39].

6. Infection

6.1. Pyogenic Liver Abscess Is a Rare Complication of IBD, Especially CD

If in the general population the incidence of liver abscess is 8–16 cases/100,000 inhabitants, in patients with CD it can reach up to 11–297 cases/100,000 inhabitants [17]. Compared to the general population, patients with liver abscesses and CD are younger and show more frequent multilocular damage [17]. The pathogenic mechanisms incriminated are portal pyemia with a secondary seeding of germs at the level of liver parenchyma or direct hepatic extension of an intra-abdominal abscess [42]. Other factors with a potential pathological role in the occurrence of liver abscesses are fistulizing disease phenotype, glucocorticoid use, abdominal surgery, diabetes mellitus and malnutrition [42]. The presence of a liver abscess can mimic a CD flare. Thus, these patients can present abdominal pain, fever, diarrhea and leukocytosis [42]. Imaging investigations can identify a liver lesion, but a positive diagnosis is established by the biochemical and bacteriological analysis of purulent aspirate [42]. Treatment involves the administration of antibiotics and in selected cases, ultrasound or CT-guided percutaneous drainage or surgical drainage [44]. Li et al. compared the effectiveness of ultrasound-guided percutaneous catheter drainage (US-PCD) vs. surgical drainage among 120 patients with liver abscesses and septic shock [45]. US-PCD was associated with a shorter extubation time, lower postoperative complication rate, shorter hospital stay and higher survival rate [45]. These authors concluded that US-PCD can be an effective therapeutic method for the drainage of liver abscesses and can improve the prognosis of these patients [45].

6.2. Reactivation of Viral Hepatitis

Treatment with corticosteroids, immunomodulators and biological agents used in patients with IBD increase the risk of opportunistic infections. Additionally, patients with a history of viral hepatitis are at risk of the reactivation of liver disease because of the immunosuppression induced by these treatments [46]. Most viral reactivations occur at the time of tapering or withdrawing of immunosuppressive therapy [47][48]. This phenomenon can be explained by the response of the immune system to the viral replication with the destruction of infected hepatocytes [47]. The use of two or more immunosuppressive drugs has been shown to be an independent predictor for viral hepatitis B reactivation [49]. Other risk factors for opportunistic infections in IBD patients are older age, malnutrition, chronic diseases, diabetes mellitus or congenital immunodeficiency [50]. The spectrum of clinical manifestations can vary from the absence of symptoms to fulminant, life-threatening hepatitis [47].
The 2021 European Crohn’s and Colitis Organization (ECCO) guidelines recommend serological screening for hepatitis A, B and C viruses, Epstein–Barr virus, varicella zoster virus, cytomegalovirus, measles virus and human immunodeficiency virus (HIV) for all IBD patients before and during immunosuppressive treatment [51]. Additionally, vaccination against hepatitis B is recommended in all seronegative patients (hepatitis B core antibody (anti-HBc) negative and hepatitis B surface antigen (HBsAg) negative) [51]. The goal of vaccination is to obtain an anti-HBs titer > 10 IU/L [51]. A meta-analysis that followed 1688 IBD patients reported a response rate to vaccination of 61% [52]. In patients with IBD and previous HBV infection (anti-HBc positive and HBsAg negative), prophylactic antiviral treatment is not recommended [48]. In patients with IBD and chronic hepatitis B, antiviral treatment with nucleoside analogues is recommended [51]. The use of antiviral treatment in these patients reduces the risk of hepatitis B reactivation from 47.4% to 7.1% [53][54]. The mortality rate in patients with hepatitis B reactivation who receive immunosuppressive treatment is approximately 5% [55].
The prevalence of hepatitis C in patients with IBD varies between 1% and 6% [56]. For patients with IBD and hepatitis C, the ECCO guidelines recommend antiviral treatment [51]. In patients using direct-acting antiviral agents (DAAs), the same guidelines recommend the careful monitoring of disease exacerbation in 2021 [51]. A multicenter retrospective study published in 2022, which followed 79 patients with IBD and hepatitis C treated with DAAs, reported an increased efficiency and safety of this antiviral treatment [56]. A sustained virologic response was obtained in 96.2% of the patients included in the study [56]. Adverse effects were reported in seven patients, five of whom were probably related to DAAs, but in 100% of cases there were mild adverse effects [47]. Thus, in patients with IBD and hepatitis C, antiviral treatment with DAAs seems to be effective, with cure rates > 90% and a good safety profile [56].

References

  1. Gizard, E.; Ford, A.C.; Bronowicki, J.P.; Peyrin-Biroulet, L. Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2014, 40, 3–15.
  2. Zhang, F.M.; Xu, C.F.; Shan, G.D.; Chen, H.T.; Xu, G.Q. Is gallstone disease associated with inflammatory bowel diseases? A meta-analysis. J. Dig. Dis. 2015, 16, 634–641.
  3. Parente, F.; Pastore, L.; Bargiggia, S.; Cucino, C.; Greco, S.; Molteni, M.; Ardizzone, S.; Porro, G.B.; Sampietro, G.M.; Giorgi, R.; et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: A large case-control study. Hepatology 2007, 45, 1267–1274.
  4. Vitek, L.; Carey, M.C. Enterohepatic cycling of bilirubin as a cause of ‘black’ pigment gallstones in adult life. Eur. J. Clin. Investig. 2003, 33, 799–810.
  5. Duboc, H.; Rajca, S.; Rainteau, D.; Benarous, D.; Maubert, M.A.; Quervain, E.; Thomas, G.; Barbu, V.; Humbert, L.; Despras, G.; et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013, 62, 531–539.
  6. Maurer, K.J.; Carey, C.; Rao, V.P.; Ge, Z.; Rogers, A.B.; Oura, T.J.; Carey, M.C.; Fox, J.G. T-cell function is critical for murine cholesterol gallstone formation. Gastroenterology 2007, 133, 1304–1315.
  7. Chen, C.H.; Lin, C.L.; Kao, C.H. Association between Inflammatory Bowel Disease and Cholelithiasis: A Nationwide Population-Based Cohort Study. Int. J. Env. Res. Public Health 2018, 15, 513.
  8. Gaspar, R.; Branco, C.C.; Macedo, G. Liver manifestations and complications in inflammatory bowel disease: A review. World J. Hepatol. 2021, 13, 1956–1967.
  9. Chew, S.S.; Ngo, T.Q.; Douglas, P.R.; Newstead, G.L.; Selby, W.; Solomon, M.J. Cholecystectomy in patients with Crohn’s ileitis. Dis. Colon. Rectum 2003, 46, 1484–1488.
  10. Navaneethan, U.; Choure, A.; Venkatesh, P.G.; Hammel, J.; Lin, J.; Goldblum, J.R.; Manilich, E.; Kiran, R.P.; Ramzi, F.H.; Shen, B. Presence of concomitant inflammatory bowel disease is associated with an increased risk of postcholecystectomy complications. Inflamm. Bowel Dis. 2012, 18, 1682–1688.
  11. Bessissow, T.; Le, N.H.; Rollet, K.; Afif, W.; Bitton, A.; Sebastiani, G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2016, 22, 1937.
  12. Saroli Palumbo, C.; Restellini, S.; Chao, C.Y.; Aruljothy, A.; Lemieux, C.; Wild, G.; Afif, W.; Lakatos, P.L.; Bitton, A.; Cocciolillo, S.; et al. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflamm. Bowel Dis. 2019, 25, 124.
  13. Rojas-Feria, M.; Castro, M.; Suárez, E.; Ampuero, J.; Romero-Gómez, M. Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver. World J. Gastroenterol. 2013, 19, 7327.
  14. Magri, S.; Paduano, D.; Chicco, F.; Cingolani, A.; Farris, C.; Delogu, G.; Tumbarello, F.; Lai, M.; Melis, A.; Casula, L.; et al. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history. Word J. Gastroenterol. 2019, 25, 5676–5686.
  15. Sourianarayanane, A.; Garg, G.; Smith, T.H.; Butt, M.I.; McCullough, A.J.; Shen, B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J. Crohns Colitis 2013, 7, e279–e285.
  16. Barbuio, R.; Milanski, M.; Bertolo, M.B.; Saad, M.J.; Velloso, L.A. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J. Endocrinol. 2007, 194, 539–550.
  17. Fousekis, F.S.; Theopistos, V.I.; Katsanos, K.H.; Tsianos, E.V.; Christodoulou, D.K. Hepatobiliary manifestations and complications in inflammatory bowel disease: A review. Gastroenterol. Res. 2018, 11, 83–94.
  18. Braun, M.; Fraser, G.M.; Kunin, M.; Salamon, F.; Tur-Kaspa, R. Mesalamine-induced granulomatous hepatitis. Am. J. Gastroenterol. 1999, 94, 1973–1974.
  19. Namias, A.; Bhalotra, R.; Donowitz, M. Reversible sulfasalazine-induced granulomatous hepatitis. J. Clin. Gastroenterol. 1981, 3, 193–198.
  20. Navaneethan, U.; Shen, B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm. Bowel Dis. 2010, 16, 1598–1619.
  21. Flamm, S.L. Granulomatous liver disease. Clin. Liver Dis. 2012, 16, 387–396.
  22. Saad, E.; Agab, M.; Ozcekirdek, E.C.; Awadelkarim, A.; Idris, I. The Diagnostic Dilemma of Acute Granulomatous Hepatitis in a Patient With Crohn’s Disease: A Case Report and Review of Literature. J. Investig. Med. High Impact. Case. Rep. 2022, 10, 23247096211069764.
  23. Kennedy, P.T.; Zakaria, N.; Modawi, S.B.; Papadopoulou, A.M.; Murray-Lyon, I.; du Bois, R.M.; Andreyev, H.J.N.; Devlin, J. Natural history of hepatic sarcoidosis and its response to treatment. Eur. J. Gastroenterol. Hepatol. 2006, 18, 721–726.
  24. Decock, A.; Van Assche, G.; Vermeire, S.; Wuyts, W.; Ferrante, M. Sarcoidosis-like lesions: Another paradoxical reaction to anti-TNF therapy? J. Crohns Colitis 2017, 11, 378–383.
  25. Gottenberg, J.E.; Merle-Vincent, F.; Bentaberry, F.; Allanore, Y.; Berenbaum, F.; Fautrel, B.; Combe, B.; Durbach, A.; Sibilia, J.; Dougados, M.; et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: A followup report of tolerability and efficacy. Arthritis Rheum. 2003, 48, 2019–2024.
  26. Meyers, S.; Janowitz, H.D.; Gumaste, V.V.; Abramson, R.G.; Berman, L.J.; Venkataseshan, V.S.; Dickman, S.H. Colchicine therapy of the renal amyloidosis of ulcerative colitis. Gastroenterology 1988, 94, 1503–1507.
  27. Sharma, P.; Aguilar, R.; Siddiqui, O.A.; Nader, M.A. Secondary systemic amyloidosis in inflammatory bowel disease: A nationwide analysis. Ann. Gastroenterol. 2017, 30, 504–511.
  28. Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations—United States, 2007–2009. MMWR Morb. Mortal. Wkly. Rep. 2012, 61, 401–404.
  29. Grainge, M.J.; West, J.; Card, T.R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: A cohort study. Lancet 2010, 375, 657–663.
  30. Miehsler, W.; Reinisch, W.; Valic, E.; Osterode, W.; Tillinger, W.; Feichtenschlager, T.; Grisar, J.; Machold, K.; Scholz, S.; Vogelsang, H.; et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004, 53, 542–548.
  31. Bruining, D.H.; Siddiki, H.A.; Fletcher, J.G.; Tremaine, W.J.; Sandborn, W.J.; Loftus, E.V., Jr. Prevalence of penetrating disease and extraintestinal manifestations of Crohn’s disease detected with CT enterography. Inflamm. Bowel Dis. 2008, 14, 1701–1706.
  32. Fichera, A.; Cicchiello, L.A.; Mendelson, D.S.; Greenstein, A.J.; Heimann, T.M. Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: A not uncommon cause of postoperative acute abdominal pain. Dis. Colon Rectum 2003, 46, 643–648.
  33. Giannotta, M.; Tapete, G.; Emmi, G.; Silvestri, E.; Milla, M. Thrombosis in inflammatory bowel diseases: What’s the link? Thromb. J. 2015, 13, 14.
  34. Kume, K.; Yamasaki, M.; Tashiro, M.; Yoshikawa, I.; Otsuki, M. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. Intern. Med. 2007, 46, 1323–1329.
  35. Alkim, H.; Ayaz, S.; Alkim, C.; Ulker, A.; Sahin, B. Continuous active state of coagulation system in patients with nonthrombotic inflammatory bowel disease. Clin. Appl. Thromb. Hemost. 2011, 17, 600–604.
  36. Collins, C.E.; Cahill, M.R.; Newland, A.C.; Rampton, D.S. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994, 106, 840–845.
  37. Zezos, P.; Kouklakis, G.; Saibil, F. Inflammatory bowel disease and thromboembolism. World J. Gastroenterol. 2014, 20, 13863–13878.
  38. Lin, H.; Bai, Z.; Meng, F.; Wu, Y.; Luo, L.; Shukla, A.; Yoshida, E.M.; Guo, X.; Qi, X. Epidemiology and Risk Factors of Portal Venous System Thrombosis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Front. Med. 2022, 8, 744505.
  39. Cheng, K.; Faye, A.S. Venous thromboembolism in inflammatory bowel disease. World J. Gastroenterol. 2020, 26, 1231–1241.
  40. Nylund, C.M.; Goudie, A.; Garza, J.M.; Crouch, G.; Denson, L.A. Venous thrombotic events in hospitalized children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2013, 56, 485–491.
  41. Faye, A.S.; Wen, T.; Ananthakrishnan, A.N.; Lichtiger, S.; Kaplan, G.G.; Friedman, A.M.; Lawlor, G.; Wright, J.D.; Attenello, F.J.; Mack, W.J.; et al. Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. Clin. Gastroenterol. Hepatol. 2020, 18, 1133–1141.
  42. Lin, J.N.; Lin, C.L.; Lin, M.C.; Lai, C.H.; Lin, H.H.; Kao, C.H. Pyogenic liver abscess in patients with inflammatory bowel disease: A nationwide cohort study. Liver Int. 2016, 36, 136.
  43. Sinagra, E.; Aragona, E.; Romano, C.; Maisano, S.; Orlando, A.; Virdone, R.; Tese, L.; Modesto, I.; Criscuoli, V.; Cottone, M. The Role of Portal Vein Thrombosis in the Clinical Course of Inflammatory Bowel Diseases: Report on Three Cases and Review of the Literature. Gastroenterol. Res. Pract. 2012, 2012, 916428.
  44. Lubbert, C.; Wiegand, J.; Karlas, T. Therapy of Liver Abscesses. Viszeralmedizin 2014, 30, 334–341.
  45. Li, S.; Luo, J.; Wang, Z.; Lv, C.; Wang, Y. Efficacy and Prognosis of Ultrasound-Guided Percutaneous Catheter Drainage in Patients with Liver Abscess Complicated with Septic Shock. Comput. Math Methods Med. 2022, 2022, 4688356.
  46. Park, S.K.; Choi, C.H.; Chun, J.; Lee, H.; Kim, E.S.; Park, J.J.; Park, C.H.; Lee, B.I.; Jung, Y.; Park, D.I.; et al. Prevention and management of viral hepatitis in inflammatory bowel disease: A clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest. Res. 2020, 18, 18–33.
  47. Sansone, S.; Guarino, M.; Castiglione, F.; Rispo, A.; Auriemma, F.; Loperto, I.; Rea, M.; Caporaso, N.; Morisco, F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J. Gastroenterol. 2014, 20, 3516–3524.
  48. Ridola, L.; Zullo, A.; Lagana, B.; Lorenzetti, R.; Migliore, A.; Pica, R.; Diamanti, A.P.; Gigliucci, G.; Scolieri, P.; Bruzzese, V. Hepatitis B (HBV) reactivation in patients receiving biologic therapy for chronic inflammatory diseases in clinical practice. Ann. Ist. Super. Sanita 2021, 57, 244–248.
  49. Perrillo, R.P. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120, 1009–1022.
  50. Dave, M.; Purohit, T.; Razonable, R.; Loftus, E.V., Jr. Opportunistic infec- tions due to inflammatory bowel disease therapy. Inflamm. Bowel Dis. 2014, 20, 196–212.
  51. Kucharzik, T.; Ellul, P.; Greuter, T.; Rahier, J.F.; Verstockt, B.; Abreu, C.; Albuquerque, A.; Allocca, M.; Esteve, M.; Farraye, F.A.; et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J. Crohn’s Colitis 2021, 15, 879–913.
  52. Jiang, H.Y.; Wang, S.Y.; Deng, M.; Li, Y.C.; Ling, Z.X.; Shao, L.; Ruan, B. Immune response to hepatitis B vac- cination among people with inflammatory bowel diseases: A systematic review and meta-analysis. Vaccine 2017, 35, 2633–2641.
  53. Loras, C.; Gisbert, J.P.; Saro, M.C.; Piqueras, M.; Sanchez-Montes, C.; Barrio, J.; Ordas, I.; Montserrat, A.; Ferreiro, R.; Zabana, Y. REPENTINA study, GETECCU group . Impact of surveillance of hepatitis B and hepatitis C in patients with inflammatory bowel disease under anti-TNF therapies: Multicentre prospective observational study . J. Crohns Colitis 2014, 8, 1529–1538.
  54. Pauly, M.P.; Tucker, L.Y.; Szpakowski, J.L.; Ready, J.B.; Baer, D.; Hwang, J.; Lok, A.S.F. Incidence of Hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. Clin. Gastroenterol. Hepatol. 2018, 16, 1964–1973.e1.
  55. Di Bisceglie, A.M.; Lok, A.; Martin, P.; Terrault, N.; Perrillo, R.P.; Hoofnagle, J.H. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune- suppressing and anticancer drugs: Just the tip of the iceberg? Hepatology 2015, 61, 703–711.
  56. Cardona, A.M.; Horta, D.; Florez-Diez, P.; Vela, M.; Mesonero, F.; Belinchon, C.R.; Garcia, M.J.; Masnou, H.; de la Pena-Negro, L.; Ferrer, C.S.; et al. P289 Evaluation of the safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease: National multicenter study (ENEIDA registry). MIC project. J. Chron’s Colitis 2022, 16, i321–i322.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Gastroenterology & Hepatology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Vlad Alexandru Ionescu
,
Gina Gheorghe
,
Valentin Nicolae Varlas
,
Ana Maria Alexandra Stanescu
,
Camelia Cristina Diaconu
View Times: 404
Revisions: 2 times (View History)
Update Date: 12 Jan 2023
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback